APA (7th ed.) Citation

Sasaki, T., Oshima, Y., Mishima, E., Ban, A., Katsuragawa, K., Nagamatsu, H., . . . Mizutani, M. (2016). Dose Reduction versus Dose-interval Prolongation in Eribulin Mesilate Monotherapy in Patients with Metastatic Breast Cancer: A Retrospective Comparative Study. YAKUGAKU ZASSHI, 136(7), 1023-1029. https://doi.org/10.1248/yakushi.15-00267

Chicago Style (17th ed.) Citation

Sasaki, Toshinori, et al. "Dose Reduction Versus Dose-interval Prolongation in Eribulin Mesilate Monotherapy in Patients with Metastatic Breast Cancer: A Retrospective Comparative Study." YAKUGAKU ZASSHI 136, no. 7 (2016): 1023-1029. https://doi.org/10.1248/yakushi.15-00267.

MLA (9th ed.) Citation

Sasaki, Toshinori, et al. "Dose Reduction Versus Dose-interval Prolongation in Eribulin Mesilate Monotherapy in Patients with Metastatic Breast Cancer: A Retrospective Comparative Study." YAKUGAKU ZASSHI, vol. 136, no. 7, 2016, pp. 1023-1029, https://doi.org/10.1248/yakushi.15-00267.